ICD-10-PCS table 3E0
Introduction, Physiological Systems and Anatomical Regions
Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Table rows
4 · Body System / Region
- 0Skin and Mucous Membranes
5 · Approach
- XExternal
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- 0Skin and Mucous Membranes
5 · Approach
- XExternal
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 0Skin and Mucous Membranes
5 · Approach
- XExternal
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- BAnesthetic Agent
- KOther Diagnostic Substance
- MPigment
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 0Skin and Mucous Membranes
5 · Approach
- XExternal
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
- FOther Enzymatic/Chemical Agent
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 0Open
6 · Substance
- 2Anti-infective
7 · Qualifier
- AAnti-Infective Envelope
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
- AAnti-Infective Envelope
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 3Percutaneous
6 · Substance
- 4Serum, Toxoid and Vaccine
7 · Qualifier
- 0Influenza Vaccine
- ZNo Qualifier
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- 3Percutaneous
6 · Substance
- VHormone
7 · Qualifier
- GInsulin
- JOther Hormone
4 · Body System / Region
- 1Subcutaneous Tissue
5 · Approach
- XExternal
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- FOther Enzymatic/Chemical Agent
4 · Body System / Region
- 2Muscle
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- 2Muscle
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 2Muscle
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 2Muscle
5 · Approach
- 3Percutaneous
6 · Substance
- 4Serum, Toxoid and Vaccine
7 · Qualifier
- 0Influenza Vaccine
- ZNo Qualifier
4 · Body System / Region
- 2Muscle
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 5Other Antineoplastic
- MMonoclonal Antibody
- PClofarabine
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 6Recombinant Human-activated Protein C
- 7Other Thrombolytic
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- FIntracirculatory Anesthetic
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- PPlatelet Inhibitor
- RAntiarrhythmic
- TDestructive Agent
- XVasopressor
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
- NBlood Brain Barrier Disruption
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- UPancreatic Islet Cells
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- VHormone
7 · Qualifier
- GInsulin
- HHuman B-type Natriuretic Peptide
- JOther Hormone
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 0Open
6 · Substance
- WImmunotherapeutic
7 · Qualifier
- KImmunostimulator
- LImmunosuppressive
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 5Other Antineoplastic
- MMonoclonal Antibody
- PClofarabine
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 6Recombinant Human-activated Protein C
- 7Other Thrombolytic
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- AStem Cells, Embryonic
- FIntracirculatory Anesthetic
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- PPlatelet Inhibitor
- RAntiarrhythmic
- TDestructive Agent
- XVasopressor
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
- NBlood Brain Barrier Disruption
- QGlucarpidase
- ROther Therapeutic Monoclonal Antibody
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- UPancreatic Islet Cells
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- VHormone
7 · Qualifier
- GInsulin
- HHuman B-type Natriuretic Peptide
- JOther Hormone
4 · Body System / Region
- 3Peripheral Vein
5 · Approach
- 3Percutaneous
6 · Substance
- WImmunotherapeutic
7 · Qualifier
- KImmunostimulator
- LImmunosuppressive
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 5Other Antineoplastic
- MMonoclonal Antibody
- PClofarabine
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 6Recombinant Human-activated Protein C
- 7Other Thrombolytic
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- FIntracirculatory Anesthetic
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- PPlatelet Inhibitor
- RAntiarrhythmic
- TDestructive Agent
- XVasopressor
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
- NBlood Brain Barrier Disruption
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- VHormone
7 · Qualifier
- GInsulin
- HHuman B-type Natriuretic Peptide
- JOther Hormone
4 · Body System / Region
- 4Central Vein
5 · Approach
- 0Open
6 · Substance
- WImmunotherapeutic
7 · Qualifier
- KImmunostimulator
- LImmunosuppressive
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 5Other Antineoplastic
- MMonoclonal Antibody
- PClofarabine
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 6Recombinant Human-activated Protein C
- 7Other Thrombolytic
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- AStem Cells, Embryonic
- FIntracirculatory Anesthetic
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- PPlatelet Inhibitor
- RAntiarrhythmic
- TDestructive Agent
- XVasopressor
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
- NBlood Brain Barrier Disruption
- QGlucarpidase
- ROther Therapeutic Monoclonal Antibody
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- VHormone
7 · Qualifier
- GInsulin
- HHuman B-type Natriuretic Peptide
- JOther Hormone
4 · Body System / Region
- 4Central Vein
5 · Approach
- 3Percutaneous
6 · Substance
- WImmunotherapeutic
7 · Qualifier
- KImmunostimulator
- LImmunosuppressive
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 5Other Antineoplastic
- MMonoclonal Antibody
- PClofarabine
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 6Recombinant Human-activated Protein C
- 7Other Thrombolytic
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- FIntracirculatory Anesthetic
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- PPlatelet Inhibitor
- RAntiarrhythmic
- TDestructive Agent
- XVasopressor
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
- NBlood Brain Barrier Disruption
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- VHormone
7 · Qualifier
- GInsulin
- HHuman B-type Natriuretic Peptide
- JOther Hormone
4 · Body System / Region
- 5Peripheral Artery
- 6Central Artery
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- WImmunotherapeutic
7 · Qualifier
- KImmunostimulator
- LImmunosuppressive
4 · Body System / Region
- 7Coronary Artery
- 8Heart
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 6Recombinant Human-activated Protein C
- 7Other Thrombolytic
4 · Body System / Region
- 7Coronary Artery
- 8Heart
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- 7Coronary Artery
- 8Heart
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- KOther Diagnostic Substance
- PPlatelet Inhibitor
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 7Coronary Artery
- 8Heart
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- 9Nose
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- 9Nose
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- 9Nose
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- 9Nose
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- ABone Marrow
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- ABone Marrow
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- BEar
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- BEar
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- BEar
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 3Anti-inflammatory
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- BEar
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- CEye
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- CEye
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- CEye
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 3Anti-inflammatory
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- MPigment
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- CEye
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- CEye
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- DMouth and Pharynx
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- DMouth and Pharynx
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- DMouth and Pharynx
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- 3Anti-inflammatory
- 4Serum, Toxoid and Vaccine
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- RAntiarrhythmic
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- DMouth and Pharynx
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- XExternal
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- EProducts of Conception
- GUpper GI
- HLower GI
- KGenitourinary Tract
- NMale Reproductive
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- EProducts of Conception
- GUpper GI
- HLower GI
- KGenitourinary Tract
- NMale Reproductive
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- EProducts of Conception
- GUpper GI
- HLower GI
- KGenitourinary Tract
- NMale Reproductive
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- EProducts of Conception
- GUpper GI
- HLower GI
- KGenitourinary Tract
- NMale Reproductive
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- EProducts of Conception
- GUpper GI
- HLower GI
- KGenitourinary Tract
- NMale Reproductive
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- EProducts of Conception
- GUpper GI
- HLower GI
- KGenitourinary Tract
- NMale Reproductive
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- FRespiratory Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- FRespiratory Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- FRespiratory Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- FRespiratory Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- FRespiratory Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- SGas
7 · Qualifier
- DNitric Oxide
- FOther Gas
4 · Body System / Region
- FRespiratory Tract
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 3Percutaneous
- 7Via Natural or Artificial Opening
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- UPancreatic Islet Cells
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- JBiliary and Pancreatic Tract
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 0Open
6 · Substance
- 5Adhesion Barrier
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 1Thrombolytic
7 · Qualifier
- 7Other Thrombolytic
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 5Adhesion Barrier
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- 5Adhesion Barrier
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- LPleural Cavity
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 0Open
6 · Substance
- 5Adhesion Barrier
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
- YHyperthermic
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 5Adhesion Barrier
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- 5Adhesion Barrier
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- MPeritoneal Cavity
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 0Open
6 · Substance
- 5Adhesion Barrier
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 5Adhesion Barrier
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- LSperm
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
- VHormone
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 3Percutaneous
6 · Substance
- QFertilized Ovum
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- 5Adhesion Barrier
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- LSperm
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
- VHormone
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- QFertilized Ovum
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- PFemale Reproductive
5 · Approach
- 8Via Natural or Artificial Opening Endoscopic
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- AStem Cells, Embryonic
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- EStem Cells, Somatic
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 0Open
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- QCranial Cavity and Brain
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 0Open
6 · Substance
- AStem Cells, Embryonic
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 0Open
6 · Substance
- EStem Cells, Somatic
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- AStem Cells, Embryonic
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 3Percutaneous
6 · Substance
- EStem Cells, Somatic
7 · Qualifier
- 0Autologous
- 1Nonautologous
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- RSpinal Canal
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- SEpidural Space
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 2High-dose Interleukin-2
- 3Low-dose Interleukin-2
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- SEpidural Space
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- SEpidural Space
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- SEpidural Space
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- SEpidural Space
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- SEpidural Space
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- TPeripheral Nerves and Plexi
- XCranial Nerves
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- BAnesthetic Agent
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- TPeripheral Nerves and Plexi
- XCranial Nerves
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- UJoints
5 · Approach
- 0Open
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- UJoints
5 · Approach
- 0Open
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- BRecombinant Bone Morphogenetic Protein
- COther Substance
4 · Body System / Region
- UJoints
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- UJoints
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- UJoints
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- UJoints
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- BRecombinant Bone Morphogenetic Protein
- COther Substance
4 · Body System / Region
- UJoints
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- UJoints
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- VBones
5 · Approach
- 0Open
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- BRecombinant Bone Morphogenetic Protein
- COther Substance
4 · Body System / Region
- VBones
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- VBones
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- VBones
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- VBones
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- BRecombinant Bone Morphogenetic Protein
- COther Substance
4 · Body System / Region
- VBones
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- WLymphatics
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- WLymphatics
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- WLymphatics
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- WLymphatics
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 2Anti-infective
7 · Qualifier
- 8Oxazolidinones
- 9Other Anti-infective
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- 3Anti-inflammatory
- 6Nutritional Substance
- 7Electrolytic and Water Balance Substance
- BAnesthetic Agent
- HRadioactive Substance
- KOther Diagnostic Substance
- NAnalgesics, Hypnotics, Sedatives
- TDestructive Agent
7 · Qualifier
- ZNo Qualifier
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 3Percutaneous
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 4Percutaneous Endoscopic
6 · Substance
- GOther Therapeutic Substance
7 · Qualifier
- COther Substance
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- 0Antineoplastic
7 · Qualifier
- 4Liquid Brachytherapy Radioisotope
- 5Other Antineoplastic
- MMonoclonal Antibody
4 · Body System / Region
- YPericardial Cavity
5 · Approach
- 7Via Natural or Artificial Opening
6 · Substance
- SGas
7 · Qualifier
- FOther Gas
All 1,066 valid codes in 3E0
- 3E00X05Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach
- 3E00X0MIntroduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
- 3E00X28Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach
- 3E00X29Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach
- 3E00X3ZIntroduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach
- 3E00X4ZIntroduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach
- 3E00XBZIntroduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach
- 3E00XGCIntroduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach
- 3E00XGFIntroduction of Other Enzymatic/Chemical Agent into Skin and Mucous Membranes, External Approach
- 3E00XKZIntroduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach
- 3E00XMZIntroduction of Pigment into Skin and Mucous Membranes, External Approach
- 3E00XNZIntroduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach
- 3E00XTZIntroduction of Destructive Agent into Skin and Mucous Membranes, External Approach
- 3E0102AIntroduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach
- 3E01305Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach
- 3E0130MIntroduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
- 3E01328Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach
- 3E01329Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach
- 3E0132AIntroduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach
- 3E0133ZIntroduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach
- 3E01340Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach
- 3E0134ZIntroduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach
- 3E0136ZIntroduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach
- 3E0137ZIntroduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach
- 3E013BZIntroduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach
- 3E013GCIntroduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach
- 3E013HZIntroduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach
- 3E013KZIntroduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach
- 3E013NZIntroduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach
- 3E013TZIntroduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach
- 3E013VGIntroduction of Insulin into Subcutaneous Tissue, Percutaneous Approach
- 3E013VJIntroduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach
- 3E01XGFIntroduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach
- 3E02305Introduction of Other Antineoplastic into Muscle, Percutaneous Approach
- 3E0230MIntroduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
- 3E02328Introduction of Oxazolidinones into Muscle, Percutaneous Approach
- 3E02329Introduction of Other Anti-infective into Muscle, Percutaneous Approach
- 3E0233ZIntroduction of Anti-inflammatory into Muscle, Percutaneous Approach
- 3E02340Introduction of Influenza Vaccine into Muscle, Percutaneous Approach
- 3E0234ZIntroduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach
- 3E0236ZIntroduction of Nutritional Substance into Muscle, Percutaneous Approach
- 3E0237ZIntroduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach
- 3E023BZIntroduction of Anesthetic Agent into Muscle, Percutaneous Approach
- 3E023GCIntroduction of Other Therapeutic Substance into Muscle, Percutaneous Approach
- 3E023HZIntroduction of Radioactive Substance into Muscle, Percutaneous Approach
- 3E023KZIntroduction of Other Diagnostic Substance into Muscle, Percutaneous Approach
- 3E023NZIntroduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach
- 3E023TZIntroduction of Destructive Agent into Muscle, Percutaneous Approach
- 3E03002Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
- 3E03003Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach
- 3E03005Introduction of Other Antineoplastic into Peripheral Vein, Open Approach
- 3E0300MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
- 3E0300PIntroduction of Clofarabine into Peripheral Vein, Open Approach
- 3E03016Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open
- 3E03017Introduction of Other Thrombolytic into Peripheral Vein, Open Approach
- 3E03028Introduction of Oxazolidinones into Peripheral Vein, Open Approach
- 3E03029Introduction of Other Anti-infective into Peripheral Vein, Open Approach
- 3E0303ZIntroduction of Anti-inflammatory into Peripheral Vein, Open Approach
- 3E0304ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach
- 3E0306ZIntroduction of Nutritional Substance into Peripheral Vein, Open Approach
- 3E0307ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach
- 3E030FZIntroduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach
- 3E030GCIntroduction of Other Therapeutic Substance into Peripheral Vein, Open Approach
- 3E030GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach
- 3E030HZIntroduction of Radioactive Substance into Peripheral Vein, Open Approach
- 3E030KZIntroduction of Other Diagnostic Substance into Peripheral Vein, Open Approach
- 3E030NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach
- 3E030PZIntroduction of Platelet Inhibitor into Peripheral Vein, Open Approach
- 3E030RZIntroduction of Antiarrhythmic into Peripheral Vein, Open Approach
- 3E030TZIntroduction of Destructive Agent into Peripheral Vein, Open Approach
- 3E030U0Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
- 3E030U1Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
- 3E030VGIntroduction of Insulin into Peripheral Vein, Open Approach
- 3E030VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach
- 3E030VJIntroduction of Other Hormone into Peripheral Vein, Open Approach
- 3E030WKIntroduction of Immunostimulator into Peripheral Vein, Open
- 3E030WLIntroduction of Immunosuppressive into Peripheral Vein, Open
- 3E030XZIntroduction of Vasopressor into Peripheral Vein, Open Approach
- 3E03302Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
- 3E03303Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
- 3E03305Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach
- 3E0330MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
- 3E0330PIntroduction of Clofarabine into Peripheral Vein, Percutaneous Approach
- 3E03316Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous
- 3E03317Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach
- 3E03328Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach
- 3E03329Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach
- 3E0333ZIntroduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach
- 3E0334ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach
- 3E0336ZIntroduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach
- 3E0337ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach
- 3E033AZIntroduction of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach
- 3E033FZIntroduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach
- 3E033GCIntroduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach
- 3E033GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach
- 3E033GQIntroduction of Glucarpidase into Peripheral Vein, Percutaneous Approach
- 3E033GRIntroduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach
- 3E033HZIntroduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach
- 3E033KZIntroduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach
- 3E033NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach
- 3E033PZIntroduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach
- 3E033RZIntroduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach
- 3E033TZIntroduction of Destructive Agent into Peripheral Vein, Percutaneous Approach
- 3E033U0Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
- 3E033U1Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
- 3E033VGIntroduction of Insulin into Peripheral Vein, Percutaneous Approach
- 3E033VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach
- 3E033VJIntroduction of Other Hormone into Peripheral Vein, Percutaneous Approach
- 3E033WKIntroduction of Immunostimulator into Peripheral Vein, Percutaneous
- 3E033WLIntroduction of Immunosuppressive into Peripheral Vein, Percutaneous
- 3E033XZIntroduction of Vasopressor into Peripheral Vein, Percutaneous Approach
- 3E04002Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
- 3E04003Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach
- 3E04005Introduction of Other Antineoplastic into Central Vein, Open Approach
- 3E0400MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
- 3E0400PIntroduction of Clofarabine into Central Vein, Open Approach
- 3E04016Introduction of Recombinant Human-activated Protein C into Central Vein, Open
- 3E04017Introduction of Other Thrombolytic into Central Vein, Open Approach
- 3E04028Introduction of Oxazolidinones into Central Vein, Open Approach
- 3E04029Introduction of Other Anti-infective into Central Vein, Open Approach
- 3E0403ZIntroduction of Anti-inflammatory into Central Vein, Open Approach
- 3E0404ZIntroduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach
- 3E0406ZIntroduction of Nutritional Substance into Central Vein, Open Approach
- 3E0407ZIntroduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach
- 3E040FZIntroduction of Intracirculatory Anesthetic into Central Vein, Open Approach
- 3E040GCIntroduction of Other Therapeutic Substance into Central Vein, Open Approach
- 3E040GNIntroduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach
- 3E040HZIntroduction of Radioactive Substance into Central Vein, Open Approach
- 3E040KZIntroduction of Other Diagnostic Substance into Central Vein, Open Approach
- 3E040NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach
- 3E040PZIntroduction of Platelet Inhibitor into Central Vein, Open Approach
- 3E040RZIntroduction of Antiarrhythmic into Central Vein, Open Approach
- 3E040TZIntroduction of Destructive Agent into Central Vein, Open Approach
- 3E040VGIntroduction of Insulin into Central Vein, Open Approach
- 3E040VHIntroduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach
- 3E040VJIntroduction of Other Hormone into Central Vein, Open Approach
- 3E040WKIntroduction of Immunostimulator into Central Vein, Open
- 3E040WLIntroduction of Immunosuppressive into Central Vein, Open
- 3E040XZIntroduction of Vasopressor into Central Vein, Open Approach
- 3E04302Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
- 3E04303Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach
- 3E04305Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
- 3E0430MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
- 3E0430PIntroduction of Clofarabine into Central Vein, Percutaneous Approach
- 3E04316Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous
- 3E04317Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach
- 3E04328Introduction of Oxazolidinones into Central Vein, Percutaneous Approach
- 3E04329Introduction of Other Anti-infective into Central Vein, Percutaneous Approach
- 3E0433ZIntroduction of Anti-inflammatory into Central Vein, Percutaneous Approach
- 3E0434ZIntroduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach
- 3E0436ZIntroduction of Nutritional Substance into Central Vein, Percutaneous Approach
- 3E0437ZIntroduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach
- 3E043AZIntroduction of Embryonic Stem Cells into Central Vein, Percutaneous Approach
- 3E043FZIntroduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach
- 3E043GCIntroduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach
- 3E043GNIntroduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach
- 3E043GQIntroduction of Glucarpidase into Central Vein, Percutaneous Approach
- 3E043GRIntroduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach
- 3E043HZIntroduction of Radioactive Substance into Central Vein, Percutaneous Approach
- 3E043KZIntroduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach
- 3E043NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach
- 3E043PZIntroduction of Platelet Inhibitor into Central Vein, Percutaneous Approach
- 3E043RZIntroduction of Antiarrhythmic into Central Vein, Percutaneous Approach
- 3E043TZIntroduction of Destructive Agent into Central Vein, Percutaneous Approach
- 3E043VGIntroduction of Insulin into Central Vein, Percutaneous Approach
- 3E043VHIntroduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach
- 3E043VJIntroduction of Other Hormone into Central Vein, Percutaneous Approach
- 3E043WKIntroduction of Immunostimulator into Central Vein, Percutaneous
- 3E043WLIntroduction of Immunosuppressive into Central Vein, Percutaneous
- 3E043XZIntroduction of Vasopressor into Central Vein, Percutaneous Approach
- 3E05002Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
- 3E05003Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach
- 3E05005Introduction of Other Antineoplastic into Peripheral Artery, Open Approach
- 3E0500MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
- 3E0500PIntroduction of Clofarabine into Peripheral Artery, Open Approach
- 3E05016Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open
- 3E05017Introduction of Other Thrombolytic into Peripheral Artery, Open Approach
- 3E05028Introduction of Oxazolidinones into Peripheral Artery, Open Approach
- 3E05029Introduction of Other Anti-infective into Peripheral Artery, Open Approach
- 3E0503ZIntroduction of Anti-inflammatory into Peripheral Artery, Open Approach
- 3E0504ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach
- 3E0506ZIntroduction of Nutritional Substance into Peripheral Artery, Open Approach
- 3E0507ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach
- 3E050FZIntroduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach
- 3E050GCIntroduction of Other Therapeutic Substance into Peripheral Artery, Open Approach
- 3E050GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach
- 3E050HZIntroduction of Radioactive Substance into Peripheral Artery, Open Approach
- 3E050KZIntroduction of Other Diagnostic Substance into Peripheral Artery, Open Approach
- 3E050NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach
- 3E050PZIntroduction of Platelet Inhibitor into Peripheral Artery, Open Approach
- 3E050RZIntroduction of Antiarrhythmic into Peripheral Artery, Open Approach
- 3E050TZIntroduction of Destructive Agent into Peripheral Artery, Open Approach
- 3E050VGIntroduction of Insulin into Peripheral Artery, Open Approach
- 3E050VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach
- 3E050VJIntroduction of Other Hormone into Peripheral Artery, Open Approach
- 3E050WKIntroduction of Immunostimulator into Peripheral Artery, Open
- 3E050WLIntroduction of Immunosuppressive into Peripheral Artery, Open
- 3E050XZIntroduction of Vasopressor into Peripheral Artery, Open Approach
- 3E05302Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
- 3E05303Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
- 3E05305Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach
- 3E0530MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
- 3E0530PIntroduction of Clofarabine into Peripheral Artery, Percutaneous Approach
- 3E05316Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous
- 3E05317Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach
- 3E05328Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach
- 3E05329Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach
- 3E0533ZIntroduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach
- 3E0534ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach
- 3E0536ZIntroduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach
- 3E0537ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach
- 3E053FZIntroduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach
- 3E053GCIntroduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach
- 3E053GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach
- 3E053HZIntroduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach
- 3E053KZIntroduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach
- 3E053NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach
- 3E053PZIntroduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach
- 3E053RZIntroduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach
- 3E053TZIntroduction of Destructive Agent into Peripheral Artery, Percutaneous Approach
- 3E053VGIntroduction of Insulin into Peripheral Artery, Percutaneous Approach
- 3E053VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach
- 3E053VJIntroduction of Other Hormone into Peripheral Artery, Percutaneous Approach
- 3E053WKIntroduction of Immunostimulator into Peripheral Artery, Percutaneous
- 3E053WLIntroduction of Immunosuppressive into Peripheral Artery, Percutaneous
- 3E053XZIntroduction of Vasopressor into Peripheral Artery, Percutaneous Approach
- 3E06002Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
- 3E06003Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach
- 3E06005Introduction of Other Antineoplastic into Central Artery, Open Approach
- 3E0600MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
- 3E0600PIntroduction of Clofarabine into Central Artery, Open Approach
- 3E06016Introduction of Recombinant Human-activated Protein C into Central Artery, Open
- 3E06017Introduction of Other Thrombolytic into Central Artery, Open Approach
- 3E06028Introduction of Oxazolidinones into Central Artery, Open Approach
- 3E06029Introduction of Other Anti-infective into Central Artery, Open Approach
- 3E0603ZIntroduction of Anti-inflammatory into Central Artery, Open Approach
- 3E0604ZIntroduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach
- 3E0606ZIntroduction of Nutritional Substance into Central Artery, Open Approach
- 3E0607ZIntroduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach
- 3E060FZIntroduction of Intracirculatory Anesthetic into Central Artery, Open Approach
- 3E060GCIntroduction of Other Therapeutic Substance into Central Artery, Open Approach
- 3E060GNIntroduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach
- 3E060HZIntroduction of Radioactive Substance into Central Artery, Open Approach
- 3E060KZIntroduction of Other Diagnostic Substance into Central Artery, Open Approach
- 3E060NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach
- 3E060PZIntroduction of Platelet Inhibitor into Central Artery, Open Approach
- 3E060RZIntroduction of Antiarrhythmic into Central Artery, Open Approach
- 3E060TZIntroduction of Destructive Agent into Central Artery, Open Approach
- 3E060VGIntroduction of Insulin into Central Artery, Open Approach
- 3E060VHIntroduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach
- 3E060VJIntroduction of Other Hormone into Central Artery, Open Approach
- 3E060WKIntroduction of Immunostimulator into Central Artery, Open
- 3E060WLIntroduction of Immunosuppressive into Central Artery, Open
- 3E060XZIntroduction of Vasopressor into Central Artery, Open Approach
- 3E06302Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
- 3E06303Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach
- 3E06305Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach
- 3E0630MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
- 3E0630PIntroduction of Clofarabine into Central Artery, Percutaneous Approach
- 3E06316Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous
- 3E06317Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach
- 3E06328Introduction of Oxazolidinones into Central Artery, Percutaneous Approach
- 3E06329Introduction of Other Anti-infective into Central Artery, Percutaneous Approach
- 3E0633ZIntroduction of Anti-inflammatory into Central Artery, Percutaneous Approach
- 3E0634ZIntroduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach
- 3E0636ZIntroduction of Nutritional Substance into Central Artery, Percutaneous Approach
- 3E0637ZIntroduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach
- 3E063FZIntroduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach
- 3E063GCIntroduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach
- 3E063GNIntroduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach
- 3E063HZIntroduction of Radioactive Substance into Central Artery, Percutaneous Approach
- 3E063KZIntroduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach
- 3E063NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach
- 3E063PZIntroduction of Platelet Inhibitor into Central Artery, Percutaneous Approach
- 3E063RZIntroduction of Antiarrhythmic into Central Artery, Percutaneous Approach
- 3E063TZIntroduction of Destructive Agent into Central Artery, Percutaneous Approach
- 3E063VGIntroduction of Insulin into Central Artery, Percutaneous Approach
- 3E063VHIntroduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach
- 3E063VJIntroduction of Other Hormone into Central Artery, Percutaneous Approach
- 3E063WKIntroduction of Immunostimulator into Central Artery, Percutaneous
- 3E063WLIntroduction of Immunosuppressive into Central Artery, Percutaneous
- 3E063XZIntroduction of Vasopressor into Central Artery, Percutaneous Approach
- 3E07016Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open
- 3E07017Introduction of Other Thrombolytic into Coronary Artery, Open Approach
- 3E070GCIntroduction of Other Therapeutic Substance into Coronary Artery, Open Approach
- 3E070KZIntroduction of Other Diagnostic Substance into Coronary Artery, Open Approach
- 3E070PZIntroduction of Platelet Inhibitor into Coronary Artery, Open Approach
- 3E07316Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous
- 3E07317Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach
- 3E073GCIntroduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach
- 3E073KZIntroduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach
- 3E073PZIntroduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach
- 3E074GCIntroduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach
- 3E08016Introduction of Recombinant Human-activated Protein C into Heart, Open
- 3E08017Introduction of Other Thrombolytic into Heart, Open Approach
- 3E080GCIntroduction of Other Therapeutic Substance into Heart, Open Approach
- 3E080KZIntroduction of Other Diagnostic Substance into Heart, Open Approach
- 3E080PZIntroduction of Platelet Inhibitor into Heart, Open Approach
- 3E08316Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous
- 3E08317Introduction of Other Thrombolytic into Heart, Percutaneous Approach
- 3E083GCIntroduction of Other Therapeutic Substance into Heart, Percutaneous Approach
- 3E083KZIntroduction of Other Diagnostic Substance into Heart, Percutaneous Approach
- 3E083PZIntroduction of Platelet Inhibitor into Heart, Percutaneous Approach
- 3E084GCIntroduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach
- 3E09305Introduction of Other Antineoplastic into Nose, Percutaneous Approach
- 3E0930MIntroduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
- 3E09328Introduction of Oxazolidinones into Nose, Percutaneous Approach
- 3E09329Introduction of Other Anti-infective into Nose, Percutaneous Approach
- 3E0933ZIntroduction of Anti-inflammatory into Nose, Percutaneous Approach
- 3E0934ZIntroduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach
- 3E093BZIntroduction of Anesthetic Agent into Nose, Percutaneous Approach
- 3E093GCIntroduction of Other Therapeutic Substance into Nose, Percutaneous Approach
- 3E093HZIntroduction of Radioactive Substance into Nose, Percutaneous Approach
- 3E093KZIntroduction of Other Diagnostic Substance into Nose, Percutaneous Approach
- 3E093NZIntroduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach
- 3E093TZIntroduction of Destructive Agent into Nose, Percutaneous Approach
- 3E09705Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening
- 3E0970MIntroduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
- 3E09728Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening
- 3E09729Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening
- 3E0973ZIntroduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening
- 3E0974ZIntroduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening
- 3E097BZIntroduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening
- 3E097GCIntroduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening
- 3E097HZIntroduction of Radioactive Substance into Nose, Via Natural or Artificial Opening
- 3E097KZIntroduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening
- 3E097NZIntroduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening
- 3E097TZIntroduction of Destructive Agent into Nose, Via Natural or Artificial Opening
- 3E09X05Introduction of Other Antineoplastic into Nose, External Approach
- 3E09X0MIntroduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
- 3E09X28Introduction of Oxazolidinones into Nose, External Approach
- 3E09X29Introduction of Other Anti-infective into Nose, External Approach
- 3E09X3ZIntroduction of Anti-inflammatory into Nose, External Approach
- 3E09X4ZIntroduction of Serum, Toxoid and Vaccine into Nose, External Approach
- 3E09XBZIntroduction of Anesthetic Agent into Nose, External Approach
- 3E09XGCIntroduction of Other Therapeutic Substance into Nose, External Approach
- 3E09XHZIntroduction of Radioactive Substance into Nose, External Approach
- 3E09XKZIntroduction of Other Diagnostic Substance into Nose, External Approach
- 3E09XNZIntroduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach
- 3E09XTZIntroduction of Destructive Agent into Nose, External Approach
- 3E0A305Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach
- 3E0A30MIntroduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
- 3E0A3GCIntroduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach
- 3E0B304Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach
- 3E0B305Introduction of Other Antineoplastic into Ear, Percutaneous Approach
- 3E0B30MIntroduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
- 3E0B328Introduction of Oxazolidinones into Ear, Percutaneous Approach
- 3E0B329Introduction of Other Anti-infective into Ear, Percutaneous Approach
- 3E0B33ZIntroduction of Anti-inflammatory into Ear, Percutaneous Approach
- 3E0B3BZIntroduction of Anesthetic Agent into Ear, Percutaneous Approach
- 3E0B3GCIntroduction of Other Therapeutic Substance into Ear, Percutaneous Approach
- 3E0B3HZIntroduction of Radioactive Substance into Ear, Percutaneous Approach
- 3E0B3KZIntroduction of Other Diagnostic Substance into Ear, Percutaneous Approach
- 3E0B3NZIntroduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach
- 3E0B3TZIntroduction of Destructive Agent into Ear, Percutaneous Approach
- 3E0B704Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening
- 3E0B705Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening
- 3E0B70MIntroduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
- 3E0B728Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening
- 3E0B729Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening
- 3E0B73ZIntroduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening
- 3E0B7BZIntroduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening
- 3E0B7GCIntroduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening
- 3E0B7HZIntroduction of Radioactive Substance into Ear, Via Natural or Artificial Opening
- 3E0B7KZIntroduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening
- 3E0B7NZIntroduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening
- 3E0B7TZIntroduction of Destructive Agent into Ear, Via Natural or Artificial Opening
- 3E0BX04Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach
- 3E0BX05Introduction of Other Antineoplastic into Ear, External Approach
- 3E0BX0MIntroduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
- 3E0BX28Introduction of Oxazolidinones into Ear, External Approach
- 3E0BX29Introduction of Other Anti-infective into Ear, External Approach
- 3E0BX3ZIntroduction of Anti-inflammatory into Ear, External Approach
- 3E0BXBZIntroduction of Anesthetic Agent into Ear, External Approach
- 3E0BXGCIntroduction of Other Therapeutic Substance into Ear, External Approach
- 3E0BXHZIntroduction of Radioactive Substance into Ear, External Approach
- 3E0BXKZIntroduction of Other Diagnostic Substance into Ear, External Approach
- 3E0BXNZIntroduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach
- 3E0BXTZIntroduction of Destructive Agent into Ear, External Approach
- 3E0C304Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach
- 3E0C305Introduction of Other Antineoplastic into Eye, Percutaneous Approach
- 3E0C30MIntroduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
- 3E0C328Introduction of Oxazolidinones into Eye, Percutaneous Approach
- 3E0C329Introduction of Other Anti-infective into Eye, Percutaneous Approach
- 3E0C33ZIntroduction of Anti-inflammatory into Eye, Percutaneous Approach
- 3E0C3BZIntroduction of Anesthetic Agent into Eye, Percutaneous Approach
- 3E0C3GCIntroduction of Other Therapeutic Substance into Eye, Percutaneous Approach
- 3E0C3HZIntroduction of Radioactive Substance into Eye, Percutaneous Approach
- 3E0C3KZIntroduction of Other Diagnostic Substance into Eye, Percutaneous Approach
- 3E0C3MZIntroduction of Pigment into Eye, Percutaneous Approach
- 3E0C3NZIntroduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach
- 3E0C3SFIntroduction of Other Gas into Eye, Percutaneous Approach
- 3E0C3TZIntroduction of Destructive Agent into Eye, Percutaneous Approach
- 3E0C704Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening
- 3E0C705Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening
- 3E0C70MIntroduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
- 3E0C728Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening
- 3E0C729Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening
- 3E0C73ZIntroduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening
- 3E0C7BZIntroduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening
- 3E0C7GCIntroduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening
- 3E0C7HZIntroduction of Radioactive Substance into Eye, Via Natural or Artificial Opening
- 3E0C7KZIntroduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening
- 3E0C7MZIntroduction of Pigment into Eye, Via Natural or Artificial Opening
- 3E0C7NZIntroduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening
- 3E0C7SFIntroduction of Other Gas into Eye, Via Natural or Artificial Opening
- 3E0C7TZIntroduction of Destructive Agent into Eye, Via Natural or Artificial Opening
- 3E0CX04Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach
- 3E0CX05Introduction of Other Antineoplastic into Eye, External Approach
- 3E0CX0MIntroduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
- 3E0CX28Introduction of Oxazolidinones into Eye, External Approach
- 3E0CX29Introduction of Other Anti-infective into Eye, External Approach
- 3E0CX3ZIntroduction of Anti-inflammatory into Eye, External Approach
- 3E0CXBZIntroduction of Anesthetic Agent into Eye, External Approach
- 3E0CXGCIntroduction of Other Therapeutic Substance into Eye, External Approach
- 3E0CXHZIntroduction of Radioactive Substance into Eye, External Approach
- 3E0CXKZIntroduction of Other Diagnostic Substance into Eye, External Approach
- 3E0CXMZIntroduction of Pigment into Eye, External Approach
- 3E0CXNZIntroduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach
- 3E0CXSFIntroduction of Other Gas into Eye, External Approach
- 3E0CXTZIntroduction of Destructive Agent into Eye, External Approach
- 3E0D304Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach
- 3E0D305Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach
- 3E0D30MIntroduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
- 3E0D328Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach
- 3E0D329Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach
- 3E0D33ZIntroduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach
- 3E0D34ZIntroduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach
- 3E0D36ZIntroduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach
- 3E0D37ZIntroduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach
- 3E0D3BZIntroduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach
- 3E0D3GCIntroduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach
- 3E0D3HZIntroduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach
- 3E0D3KZIntroduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach
- 3E0D3NZIntroduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach
- 3E0D3RZIntroduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach
- 3E0D3TZIntroduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach
- 3E0D704Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D705Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D70MIntroduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D728Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D729Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D73ZIntroduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D74ZIntroduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D76ZIntroduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D77ZIntroduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7BZIntroduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7GCIntroduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7HZIntroduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7KZIntroduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7NZIntroduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7RZIntroduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0D7TZIntroduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0DX04Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach
- 3E0DX05Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach
- 3E0DX0MIntroduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
- 3E0DX28Introduction of Oxazolidinones into Mouth and Pharynx, External Approach
- 3E0DX29Introduction of Other Anti-infective into Mouth and Pharynx, External Approach
- 3E0DX3ZIntroduction of Anti-inflammatory into Mouth and Pharynx, External Approach
- 3E0DX4ZIntroduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach
- 3E0DX6ZIntroduction of Nutritional Substance into Mouth and Pharynx, External Approach
- 3E0DX7ZIntroduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach
- 3E0DXBZIntroduction of Anesthetic Agent into Mouth and Pharynx, External Approach
- 3E0DXGCIntroduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach
- 3E0DXHZIntroduction of Radioactive Substance into Mouth and Pharynx, External Approach
- 3E0DXKZIntroduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach
- 3E0DXNZIntroduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach
- 3E0DXRZIntroduction of Antiarrhythmic into Mouth and Pharynx, External Approach
- 3E0DXTZIntroduction of Destructive Agent into Mouth and Pharynx, External Approach
- 3E0E304Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach
- 3E0E305Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach
- 3E0E30MIntroduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
- 3E0E328Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach
- 3E0E329Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach
- 3E0E33ZIntroduction of Anti-inflammatory into Products of Conception, Percutaneous Approach
- 3E0E36ZIntroduction of Nutritional Substance into Products of Conception, Percutaneous Approach
- 3E0E37ZIntroduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach
- 3E0E3BZIntroduction of Anesthetic Agent into Products of Conception, Percutaneous Approach
- 3E0E3GCIntroduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach
- 3E0E3HZIntroduction of Radioactive Substance into Products of Conception, Percutaneous Approach
- 3E0E3KZIntroduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach
- 3E0E3NZIntroduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach
- 3E0E3SFIntroduction of Other Gas into Products of Conception, Percutaneous Approach
- 3E0E3TZIntroduction of Destructive Agent into Products of Conception, Percutaneous Approach
- 3E0E4GCIntroduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach
- 3E0E704Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening
- 3E0E705Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening
- 3E0E70MIntroduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
- 3E0E728Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening
- 3E0E729Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening
- 3E0E73ZIntroduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening
- 3E0E76ZIntroduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening
- 3E0E77ZIntroduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening
- 3E0E7BZIntroduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening
- 3E0E7GCIntroduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening
- 3E0E7HZIntroduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening
- 3E0E7KZIntroduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening
- 3E0E7NZIntroduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening
- 3E0E7SFIntroduction of Other Gas into Products of Conception, Via Natural or Artificial Opening
- 3E0E7TZIntroduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening
- 3E0E804Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E805Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E80MIntroduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E828Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E829Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E83ZIntroduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E86ZIntroduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E87ZIntroduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8BZIntroduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8GCIntroduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8HZIntroduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8KZIntroduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8NZIntroduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8SFIntroduction of Other Gas into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0E8TZIntroduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0F304Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Percutaneous Approach
- 3E0F305Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach
- 3E0F30MIntroduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach
- 3E0F328Introduction of Oxazolidinones into Respiratory Tract, Percutaneous Approach
- 3E0F329Introduction of Other Anti-infective into Respiratory Tract, Percutaneous Approach
- 3E0F33ZIntroduction of Anti-inflammatory into Respiratory Tract, Percutaneous Approach
- 3E0F36ZIntroduction of Nutritional Substance into Respiratory Tract, Percutaneous Approach
- 3E0F37ZIntroduction of Electrolytic and Water Balance Substance into Respiratory Tract, Percutaneous Approach
- 3E0F3BZIntroduction of Anesthetic Agent into Respiratory Tract, Percutaneous Approach
- 3E0F3GCIntroduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Approach
- 3E0F3HZIntroduction of Radioactive Substance into Respiratory Tract, Percutaneous Approach
- 3E0F3KZIntroduction of Other Diagnostic Substance into Respiratory Tract, Percutaneous Approach
- 3E0F3NZIntroduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Percutaneous Approach
- 3E0F3SDIntroduction of Nitric Oxide Gas into Respiratory Tract, Percutaneous Approach
- 3E0F3SFIntroduction of Other Gas into Respiratory Tract, Percutaneous Approach
- 3E0F3TZIntroduction of Destructive Agent into Respiratory Tract, Percutaneous Approach
- 3E0F4GCIntroduction of Other Therapeutic Substance into Respiratory Tract, Percutaneous Endoscopic Approach
- 3E0F704Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F705Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F70MIntroduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F728Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F729Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F73ZIntroduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F76ZIntroduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F77ZIntroduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7BZIntroduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7GCIntroduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7HZIntroduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7KZIntroduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7NZIntroduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7SDIntroduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7SFIntroduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F7TZIntroduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F804Introduction of Liquid Brachytherapy Radioisotope into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F805Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F80MIntroduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F828Introduction of Oxazolidinones into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F829Introduction of Other Anti-infective into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F83ZIntroduction of Anti-inflammatory into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F86ZIntroduction of Nutritional Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F87ZIntroduction of Electrolytic and Water Balance Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8BZIntroduction of Anesthetic Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8GCIntroduction of Other Therapeutic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8HZIntroduction of Radioactive Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8KZIntroduction of Other Diagnostic Substance into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8NZIntroduction of Analgesics, Hypnotics, Sedatives into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8SDIntroduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8SFIntroduction of Other Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0F8TZIntroduction of Destructive Agent into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0G304Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Percutaneous Approach
- 3E0G305Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach
- 3E0G30MIntroduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach
- 3E0G328Introduction of Oxazolidinones into Upper GI, Percutaneous Approach
- 3E0G329Introduction of Other Anti-infective into Upper GI, Percutaneous Approach
- 3E0G33ZIntroduction of Anti-inflammatory into Upper GI, Percutaneous Approach
- 3E0G36ZIntroduction of Nutritional Substance into Upper GI, Percutaneous Approach
- 3E0G37ZIntroduction of Electrolytic and Water Balance Substance into Upper GI, Percutaneous Approach
- 3E0G3BZIntroduction of Anesthetic Agent into Upper GI, Percutaneous Approach
- 3E0G3GCIntroduction of Other Therapeutic Substance into Upper GI, Percutaneous Approach
- 3E0G3HZIntroduction of Radioactive Substance into Upper GI, Percutaneous Approach
- 3E0G3KZIntroduction of Other Diagnostic Substance into Upper GI, Percutaneous Approach
- 3E0G3NZIntroduction of Analgesics, Hypnotics, Sedatives into Upper GI, Percutaneous Approach
- 3E0G3SFIntroduction of Other Gas into Upper GI, Percutaneous Approach
- 3E0G3TZIntroduction of Destructive Agent into Upper GI, Percutaneous Approach
- 3E0G4GCIntroduction of Other Therapeutic Substance into Upper GI, Percutaneous Endoscopic Approach
- 3E0G704Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening
- 3E0G705Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening
- 3E0G70MIntroduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening
- 3E0G728Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening
- 3E0G729Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening
- 3E0G73ZIntroduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening
- 3E0G76ZIntroduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening
- 3E0G77ZIntroduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening
- 3E0G7BZIntroduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening
- 3E0G7GCIntroduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening
- 3E0G7HZIntroduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening
- 3E0G7KZIntroduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening
- 3E0G7NZIntroduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening
- 3E0G7SFIntroduction of Other Gas into Upper GI, Via Natural or Artificial Opening
- 3E0G7TZIntroduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening
- 3E0G804Introduction of Liquid Brachytherapy Radioisotope into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G805Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G80MIntroduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G828Introduction of Oxazolidinones into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G829Introduction of Other Anti-infective into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G83ZIntroduction of Anti-inflammatory into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G86ZIntroduction of Nutritional Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G87ZIntroduction of Electrolytic and Water Balance Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8BZIntroduction of Anesthetic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8GCIntroduction of Other Therapeutic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8HZIntroduction of Radioactive Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8KZIntroduction of Other Diagnostic Substance into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8NZIntroduction of Analgesics, Hypnotics, Sedatives into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8SFIntroduction of Other Gas into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0G8TZIntroduction of Destructive Agent into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0H304Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Percutaneous Approach
- 3E0H305Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach
- 3E0H30MIntroduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach
- 3E0H328Introduction of Oxazolidinones into Lower GI, Percutaneous Approach
- 3E0H329Introduction of Other Anti-infective into Lower GI, Percutaneous Approach
- 3E0H33ZIntroduction of Anti-inflammatory into Lower GI, Percutaneous Approach
- 3E0H36ZIntroduction of Nutritional Substance into Lower GI, Percutaneous Approach
- 3E0H37ZIntroduction of Electrolytic and Water Balance Substance into Lower GI, Percutaneous Approach
- 3E0H3BZIntroduction of Anesthetic Agent into Lower GI, Percutaneous Approach
- 3E0H3GCIntroduction of Other Therapeutic Substance into Lower GI, Percutaneous Approach
- 3E0H3HZIntroduction of Radioactive Substance into Lower GI, Percutaneous Approach
- 3E0H3KZIntroduction of Other Diagnostic Substance into Lower GI, Percutaneous Approach
- 3E0H3NZIntroduction of Analgesics, Hypnotics, Sedatives into Lower GI, Percutaneous Approach
- 3E0H3SFIntroduction of Other Gas into Lower GI, Percutaneous Approach
- 3E0H3TZIntroduction of Destructive Agent into Lower GI, Percutaneous Approach
- 3E0H4GCIntroduction of Other Therapeutic Substance into Lower GI, Percutaneous Endoscopic Approach
- 3E0H704Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening
- 3E0H705Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening
- 3E0H70MIntroduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening
- 3E0H728Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening
- 3E0H729Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening
- 3E0H73ZIntroduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening
- 3E0H76ZIntroduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening
- 3E0H77ZIntroduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening
- 3E0H7BZIntroduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening
- 3E0H7GCIntroduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening
- 3E0H7HZIntroduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening
- 3E0H7KZIntroduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening
- 3E0H7NZIntroduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening
- 3E0H7SFIntroduction of Other Gas into Lower GI, Via Natural or Artificial Opening
- 3E0H7TZIntroduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening
- 3E0H804Introduction of Liquid Brachytherapy Radioisotope into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H805Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H80MIntroduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H828Introduction of Oxazolidinones into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H829Introduction of Other Anti-infective into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H83ZIntroduction of Anti-inflammatory into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H86ZIntroduction of Nutritional Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H87ZIntroduction of Electrolytic and Water Balance Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8BZIntroduction of Anesthetic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8GCIntroduction of Other Therapeutic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8HZIntroduction of Radioactive Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8KZIntroduction of Other Diagnostic Substance into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8NZIntroduction of Analgesics, Hypnotics, Sedatives into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8SFIntroduction of Other Gas into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0H8TZIntroduction of Destructive Agent into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0J304Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J305Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J30MIntroduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J328Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J329Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J33ZIntroduction of Anti-inflammatory into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J36ZIntroduction of Nutritional Substance into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J37ZIntroduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3BZIntroduction of Anesthetic Agent into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3GCIntroduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3HZIntroduction of Radioactive Substance into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3KZIntroduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3NZIntroduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3SFIntroduction of Other Gas into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3TZIntroduction of Destructive Agent into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3U0Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J3U1Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J4GCIntroduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Percutaneous Endoscopic Approach
- 3E0J704Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J705Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J70MIntroduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J728Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J729Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J73ZIntroduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J76ZIntroduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J77ZIntroduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7BZIntroduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7GCIntroduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7HZIntroduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7KZIntroduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7NZIntroduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7SFIntroduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7TZIntroduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7U0Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J7U1Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J804Introduction of Liquid Brachytherapy Radioisotope into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J805Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J80MIntroduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J828Introduction of Oxazolidinones into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J829Introduction of Other Anti-infective into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J83ZIntroduction of Anti-inflammatory into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J86ZIntroduction of Nutritional Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J87ZIntroduction of Electrolytic and Water Balance Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8BZIntroduction of Anesthetic Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8GCIntroduction of Other Therapeutic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8HZIntroduction of Radioactive Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8KZIntroduction of Other Diagnostic Substance into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8NZIntroduction of Analgesics, Hypnotics, Sedatives into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8SFIntroduction of Other Gas into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8TZIntroduction of Destructive Agent into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8U0Introduction of Autologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0J8U1Introduction of Nonautologous Pancreatic Islet Cells into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K304Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Percutaneous Approach
- 3E0K305Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach
- 3E0K30MIntroduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach
- 3E0K328Introduction of Oxazolidinones into Genitourinary Tract, Percutaneous Approach
- 3E0K329Introduction of Other Anti-infective into Genitourinary Tract, Percutaneous Approach
- 3E0K33ZIntroduction of Anti-inflammatory into Genitourinary Tract, Percutaneous Approach
- 3E0K36ZIntroduction of Nutritional Substance into Genitourinary Tract, Percutaneous Approach
- 3E0K37ZIntroduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Percutaneous Approach
- 3E0K3BZIntroduction of Anesthetic Agent into Genitourinary Tract, Percutaneous Approach
- 3E0K3GCIntroduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Approach
- 3E0K3HZIntroduction of Radioactive Substance into Genitourinary Tract, Percutaneous Approach
- 3E0K3KZIntroduction of Other Diagnostic Substance into Genitourinary Tract, Percutaneous Approach
- 3E0K3NZIntroduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Percutaneous Approach
- 3E0K3SFIntroduction of Other Gas into Genitourinary Tract, Percutaneous Approach
- 3E0K3TZIntroduction of Destructive Agent into Genitourinary Tract, Percutaneous Approach
- 3E0K4GCIntroduction of Other Therapeutic Substance into Genitourinary Tract, Percutaneous Endoscopic Approach
- 3E0K704Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K705Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K70MIntroduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K728Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K729Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K73ZIntroduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K76ZIntroduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K77ZIntroduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7BZIntroduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7GCIntroduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7HZIntroduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7KZIntroduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7NZIntroduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7SFIntroduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K7TZIntroduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K804Introduction of Liquid Brachytherapy Radioisotope into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K805Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K80MIntroduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K828Introduction of Oxazolidinones into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K829Introduction of Other Anti-infective into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K83ZIntroduction of Anti-inflammatory into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K86ZIntroduction of Nutritional Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K87ZIntroduction of Electrolytic and Water Balance Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8BZIntroduction of Anesthetic Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8GCIntroduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8HZIntroduction of Radioactive Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8KZIntroduction of Other Diagnostic Substance into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8NZIntroduction of Analgesics, Hypnotics, Sedatives into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8SFIntroduction of Other Gas into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K8TZIntroduction of Destructive Agent into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0L05ZIntroduction of Adhesion Barrier into Pleural Cavity, Open Approach
- 3E0L304Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Percutaneous Approach
- 3E0L305Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach
- 3E0L30MIntroduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach
- 3E0L317Introduction of Other Thrombolytic into Pleural Cavity, Percutaneous Approach
- 3E0L328Introduction of Oxazolidinones into Pleural Cavity, Percutaneous Approach
- 3E0L329Introduction of Other Anti-infective into Pleural Cavity, Percutaneous Approach
- 3E0L33ZIntroduction of Anti-inflammatory into Pleural Cavity, Percutaneous Approach
- 3E0L35ZIntroduction of Adhesion Barrier into Pleural Cavity, Percutaneous Approach
- 3E0L36ZIntroduction of Nutritional Substance into Pleural Cavity, Percutaneous Approach
- 3E0L37ZIntroduction of Electrolytic and Water Balance Substance into Pleural Cavity, Percutaneous Approach
- 3E0L3BZIntroduction of Anesthetic Agent into Pleural Cavity, Percutaneous Approach
- 3E0L3GCIntroduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Approach
- 3E0L3HZIntroduction of Radioactive Substance into Pleural Cavity, Percutaneous Approach
- 3E0L3KZIntroduction of Other Diagnostic Substance into Pleural Cavity, Percutaneous Approach
- 3E0L3NZIntroduction of Analgesics, Hypnotics, Sedatives into Pleural Cavity, Percutaneous Approach
- 3E0L3SFIntroduction of Other Gas into Pleural Cavity, Percutaneous Approach
- 3E0L3TZIntroduction of Destructive Agent into Pleural Cavity, Percutaneous Approach
- 3E0L45ZIntroduction of Adhesion Barrier into Pleural Cavity, Percutaneous Endoscopic Approach
- 3E0L4GCIntroduction of Other Therapeutic Substance into Pleural Cavity, Percutaneous Endoscopic Approach
- 3E0L704Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Via Natural or Artificial Opening
- 3E0L705Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening
- 3E0L70MIntroduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening
- 3E0L7SFIntroduction of Other Gas into Pleural Cavity, Via Natural or Artificial Opening
- 3E0M05ZIntroduction of Adhesion Barrier into Peritoneal Cavity, Open Approach
- 3E0M304Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Percutaneous Approach
- 3E0M305Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach
- 3E0M30MIntroduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach
- 3E0M30YIntroduction of Hyperthermic Antineoplastic into Peritoneal Cavity, Percutaneous Approach
- 3E0M328Introduction of Oxazolidinones into Peritoneal Cavity, Percutaneous Approach
- 3E0M329Introduction of Other Anti-infective into Peritoneal Cavity, Percutaneous Approach
- 3E0M33ZIntroduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach
- 3E0M35ZIntroduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Approach
- 3E0M36ZIntroduction of Nutritional Substance into Peritoneal Cavity, Percutaneous Approach
- 3E0M37ZIntroduction of Electrolytic and Water Balance Substance into Peritoneal Cavity, Percutaneous Approach
- 3E0M3BZIntroduction of Anesthetic Agent into Peritoneal Cavity, Percutaneous Approach
- 3E0M3GCIntroduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Approach
- 3E0M3HZIntroduction of Radioactive Substance into Peritoneal Cavity, Percutaneous Approach
- 3E0M3KZIntroduction of Other Diagnostic Substance into Peritoneal Cavity, Percutaneous Approach
- 3E0M3NZIntroduction of Analgesics, Hypnotics, Sedatives into Peritoneal Cavity, Percutaneous Approach
- 3E0M3SFIntroduction of Other Gas into Peritoneal Cavity, Percutaneous Approach
- 3E0M3TZIntroduction of Destructive Agent into Peritoneal Cavity, Percutaneous Approach
- 3E0M45ZIntroduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Endoscopic Approach
- 3E0M4GCIntroduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Endoscopic Approach
- 3E0M704Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Via Natural or Artificial Opening
- 3E0M705Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening
- 3E0M70MIntroduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening
- 3E0M7SFIntroduction of Other Gas into Peritoneal Cavity, Via Natural or Artificial Opening
- 3E0N304Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Percutaneous Approach
- 3E0N305Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach
- 3E0N30MIntroduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach
- 3E0N328Introduction of Oxazolidinones into Male Reproductive, Percutaneous Approach
- 3E0N329Introduction of Other Anti-infective into Male Reproductive, Percutaneous Approach
- 3E0N33ZIntroduction of Anti-inflammatory into Male Reproductive, Percutaneous Approach
- 3E0N36ZIntroduction of Nutritional Substance into Male Reproductive, Percutaneous Approach
- 3E0N37ZIntroduction of Electrolytic and Water Balance Substance into Male Reproductive, Percutaneous Approach
- 3E0N3BZIntroduction of Anesthetic Agent into Male Reproductive, Percutaneous Approach
- 3E0N3GCIntroduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Approach
- 3E0N3HZIntroduction of Radioactive Substance into Male Reproductive, Percutaneous Approach
- 3E0N3KZIntroduction of Other Diagnostic Substance into Male Reproductive, Percutaneous Approach
- 3E0N3NZIntroduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Percutaneous Approach
- 3E0N3SFIntroduction of Other Gas into Male Reproductive, Percutaneous Approach
- 3E0N3TZIntroduction of Destructive Agent into Male Reproductive, Percutaneous Approach
- 3E0N4GCIntroduction of Other Therapeutic Substance into Male Reproductive, Percutaneous Endoscopic Approach
- 3E0N704Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening
- 3E0N705Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening
- 3E0N70MIntroduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening
- 3E0N728Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening
- 3E0N729Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening
- 3E0N73ZIntroduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening
- 3E0N76ZIntroduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening
- 3E0N77ZIntroduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7BZIntroduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7GCIntroduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7HZIntroduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7KZIntroduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7NZIntroduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7SFIntroduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening
- 3E0N7TZIntroduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening
- 3E0N804Introduction of Liquid Brachytherapy Radioisotope into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N805Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N80MIntroduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N828Introduction of Oxazolidinones into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N829Introduction of Other Anti-infective into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N83ZIntroduction of Anti-inflammatory into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N86ZIntroduction of Nutritional Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N87ZIntroduction of Electrolytic and Water Balance Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8BZIntroduction of Anesthetic Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8GCIntroduction of Other Therapeutic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8HZIntroduction of Radioactive Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8KZIntroduction of Other Diagnostic Substance into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8NZIntroduction of Analgesics, Hypnotics, Sedatives into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8SFIntroduction of Other Gas into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0N8TZIntroduction of Destructive Agent into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P05ZIntroduction of Adhesion Barrier into Female Reproductive, Open Approach
- 3E0P304Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Percutaneous Approach
- 3E0P305Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach
- 3E0P30MIntroduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach
- 3E0P328Introduction of Oxazolidinones into Female Reproductive, Percutaneous Approach
- 3E0P329Introduction of Other Anti-infective into Female Reproductive, Percutaneous Approach
- 3E0P33ZIntroduction of Anti-inflammatory into Female Reproductive, Percutaneous Approach
- 3E0P35ZIntroduction of Adhesion Barrier into Female Reproductive, Percutaneous Approach
- 3E0P36ZIntroduction of Nutritional Substance into Female Reproductive, Percutaneous Approach
- 3E0P37ZIntroduction of Electrolytic and Water Balance Substance into Female Reproductive, Percutaneous Approach
- 3E0P3BZIntroduction of Anesthetic Agent into Female Reproductive, Percutaneous Approach
- 3E0P3GCIntroduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Approach
- 3E0P3HZIntroduction of Radioactive Substance into Female Reproductive, Percutaneous Approach
- 3E0P3KZIntroduction of Other Diagnostic Substance into Female Reproductive, Percutaneous Approach
- 3E0P3LZIntroduction of Sperm into Female Reproductive, Percutaneous Approach
- 3E0P3NZIntroduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Percutaneous Approach
- 3E0P3Q0Introduction of Autologous Fertilized Ovum into Female Reproductive, Percutaneous Approach
- 3E0P3Q1Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Percutaneous Approach
- 3E0P3SFIntroduction of Other Gas into Female Reproductive, Percutaneous Approach
- 3E0P3TZIntroduction of Destructive Agent into Female Reproductive, Percutaneous Approach
- 3E0P3VZIntroduction of Hormone into Female Reproductive, Percutaneous Approach
- 3E0P45ZIntroduction of Adhesion Barrier into Female Reproductive, Percutaneous Endoscopic Approach
- 3E0P4GCIntroduction of Other Therapeutic Substance into Female Reproductive, Percutaneous Endoscopic Approach
- 3E0P704Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening
- 3E0P705Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening
- 3E0P70MIntroduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening
- 3E0P728Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening
- 3E0P729Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening
- 3E0P73ZIntroduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening
- 3E0P76ZIntroduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening
- 3E0P77ZIntroduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7BZIntroduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7GCIntroduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7HZIntroduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7KZIntroduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7LZIntroduction of Sperm into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7NZIntroduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7Q0Introduction of Autologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7Q1Introduction of Nonautologous Fertilized Ovum into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7SFIntroduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7TZIntroduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening
- 3E0P7VZIntroduction of Hormone into Female Reproductive, Via Natural or Artificial Opening
- 3E0P804Introduction of Liquid Brachytherapy Radioisotope into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P805Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P80MIntroduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P828Introduction of Oxazolidinones into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P829Introduction of Other Anti-infective into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P83ZIntroduction of Anti-inflammatory into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P86ZIntroduction of Nutritional Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P87ZIntroduction of Electrolytic and Water Balance Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8BZIntroduction of Anesthetic Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8GCIntroduction of Other Therapeutic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8HZIntroduction of Radioactive Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8KZIntroduction of Other Diagnostic Substance into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8NZIntroduction of Analgesics, Hypnotics, Sedatives into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8SFIntroduction of Other Gas into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P8TZIntroduction of Destructive Agent into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0Q004Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Open Approach
- 3E0Q005Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach
- 3E0Q00MIntroduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach
- 3E0Q028Introduction of Oxazolidinones into Cranial Cavity and Brain, Open Approach
- 3E0Q029Introduction of Other Anti-infective into Cranial Cavity and Brain, Open Approach
- 3E0Q03ZIntroduction of Anti-inflammatory into Cranial Cavity and Brain, Open Approach
- 3E0Q06ZIntroduction of Nutritional Substance into Cranial Cavity and Brain, Open Approach
- 3E0Q07ZIntroduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Open Approach
- 3E0Q0AZIntroduction of Embryonic Stem Cells into Cranial Cavity and Brain, Open Approach
- 3E0Q0BZIntroduction of Anesthetic Agent into Cranial Cavity and Brain, Open Approach
- 3E0Q0E0Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach
- 3E0Q0E1Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Open Approach
- 3E0Q0GCIntroduction of Other Therapeutic Substance into Cranial Cavity and Brain, Open Approach
- 3E0Q0HZIntroduction of Radioactive Substance into Cranial Cavity and Brain, Open Approach
- 3E0Q0KZIntroduction of Other Diagnostic Substance into Cranial Cavity and Brain, Open Approach
- 3E0Q0NZIntroduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Open Approach
- 3E0Q0SFIntroduction of Other Gas into Cranial Cavity and Brain, Open Approach
- 3E0Q0TZIntroduction of Destructive Agent into Cranial Cavity and Brain, Open Approach
- 3E0Q304Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q305Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q30MIntroduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q328Introduction of Oxazolidinones into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q329Introduction of Other Anti-infective into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q33ZIntroduction of Anti-inflammatory into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q36ZIntroduction of Nutritional Substance into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q37ZIntroduction of Electrolytic and Water Balance Substance into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3AZIntroduction of Embryonic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3BZIntroduction of Anesthetic Agent into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3E0Introduction of Autologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3E1Introduction of Nonautologous Somatic Stem Cells into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3GCIntroduction of Other Therapeutic Substance into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3HZIntroduction of Radioactive Substance into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3KZIntroduction of Other Diagnostic Substance into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3NZIntroduction of Analgesics, Hypnotics, Sedatives into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3SFIntroduction of Other Gas into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q3TZIntroduction of Destructive Agent into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q704Introduction of Liquid Brachytherapy Radioisotope into Cranial Cavity and Brain, Via Natural or Artificial Opening
- 3E0Q705Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening
- 3E0Q70MIntroduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening
- 3E0Q7SFIntroduction of Other Gas into Cranial Cavity and Brain, Via Natural or Artificial Opening
- 3E0R0AZIntroduction of Embryonic Stem Cells into Spinal Canal, Open Approach
- 3E0R0E0Introduction of Autologous Somatic Stem Cells into Spinal Canal, Open Approach
- 3E0R0E1Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Open Approach
- 3E0R302Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
- 3E0R303Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
- 3E0R304Introduction of Liquid Brachytherapy Radioisotope into Spinal Canal, Percutaneous Approach
- 3E0R305Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach
- 3E0R30MIntroduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach
- 3E0R328Introduction of Oxazolidinones into Spinal Canal, Percutaneous Approach
- 3E0R329Introduction of Other Anti-infective into Spinal Canal, Percutaneous Approach
- 3E0R33ZIntroduction of Anti-inflammatory into Spinal Canal, Percutaneous Approach
- 3E0R36ZIntroduction of Nutritional Substance into Spinal Canal, Percutaneous Approach
- 3E0R37ZIntroduction of Electrolytic and Water Balance Substance into Spinal Canal, Percutaneous Approach
- 3E0R3AZIntroduction of Embryonic Stem Cells into Spinal Canal, Percutaneous Approach
- 3E0R3BZIntroduction of Anesthetic Agent into Spinal Canal, Percutaneous Approach
- 3E0R3E0Introduction of Autologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach
- 3E0R3E1Introduction of Nonautologous Somatic Stem Cells into Spinal Canal, Percutaneous Approach
- 3E0R3GCIntroduction of Other Therapeutic Substance into Spinal Canal, Percutaneous Approach
- 3E0R3HZIntroduction of Radioactive Substance into Spinal Canal, Percutaneous Approach
- 3E0R3KZIntroduction of Other Diagnostic Substance into Spinal Canal, Percutaneous Approach
- 3E0R3NZIntroduction of Analgesics, Hypnotics, Sedatives into Spinal Canal, Percutaneous Approach
- 3E0R3SFIntroduction of Other Gas into Spinal Canal, Percutaneous Approach
- 3E0R3TZIntroduction of Destructive Agent into Spinal Canal, Percutaneous Approach
- 3E0R7SFIntroduction of Other Gas into Spinal Canal, Via Natural or Artificial Opening
- 3E0S302Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach
- 3E0S303Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach
- 3E0S304Introduction of Liquid Brachytherapy Radioisotope into Epidural Space, Percutaneous Approach
- 3E0S305Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach
- 3E0S30MIntroduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach
- 3E0S328Introduction of Oxazolidinones into Epidural Space, Percutaneous Approach
- 3E0S329Introduction of Other Anti-infective into Epidural Space, Percutaneous Approach
- 3E0S33ZIntroduction of Anti-inflammatory into Epidural Space, Percutaneous Approach
- 3E0S36ZIntroduction of Nutritional Substance into Epidural Space, Percutaneous Approach
- 3E0S37ZIntroduction of Electrolytic and Water Balance Substance into Epidural Space, Percutaneous Approach
- 3E0S3BZIntroduction of Anesthetic Agent into Epidural Space, Percutaneous Approach
- 3E0S3GCIntroduction of Other Therapeutic Substance into Epidural Space, Percutaneous Approach
- 3E0S3HZIntroduction of Radioactive Substance into Epidural Space, Percutaneous Approach
- 3E0S3KZIntroduction of Other Diagnostic Substance into Epidural Space, Percutaneous Approach
- 3E0S3NZIntroduction of Analgesics, Hypnotics, Sedatives into Epidural Space, Percutaneous Approach
- 3E0S3SFIntroduction of Other Gas into Epidural Space, Percutaneous Approach
- 3E0S3TZIntroduction of Destructive Agent into Epidural Space, Percutaneous Approach
- 3E0S7SFIntroduction of Other Gas into Epidural Space, Via Natural or Artificial Opening
- 3E0T33ZIntroduction of Anti-inflammatory into Peripheral Nerves and Plexi, Percutaneous Approach
- 3E0T3BZIntroduction of Anesthetic Agent into Peripheral Nerves and Plexi, Percutaneous Approach
- 3E0T3GCIntroduction of Other Therapeutic Substance into Peripheral Nerves and Plexi, Percutaneous Approach
- 3E0T3TZIntroduction of Destructive Agent into Peripheral Nerves and Plexi, Percutaneous Approach
- 3E0U028Introduction of Oxazolidinones into Joints, Open Approach
- 3E0U029Introduction of Other Anti-infective into Joints, Open Approach
- 3E0U0GBIntroduction of Recombinant Bone Morphogenetic Protein into Joints, Open Approach
- 3E0U0GCIntroduction of Other Therapeutic Substance into Joints, Open Approach
- 3E0U304Introduction of Liquid Brachytherapy Radioisotope into Joints, Percutaneous Approach
- 3E0U305Introduction of Other Antineoplastic into Joints, Percutaneous Approach
- 3E0U30MIntroduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach
- 3E0U328Introduction of Oxazolidinones into Joints, Percutaneous Approach
- 3E0U329Introduction of Other Anti-infective into Joints, Percutaneous Approach
- 3E0U33ZIntroduction of Anti-inflammatory into Joints, Percutaneous Approach
- 3E0U36ZIntroduction of Nutritional Substance into Joints, Percutaneous Approach
- 3E0U37ZIntroduction of Electrolytic and Water Balance Substance into Joints, Percutaneous Approach
- 3E0U3BZIntroduction of Anesthetic Agent into Joints, Percutaneous Approach
- 3E0U3GBIntroduction of Recombinant Bone Morphogenetic Protein into Joints, Percutaneous Approach
- 3E0U3GCIntroduction of Other Therapeutic Substance into Joints, Percutaneous Approach
- 3E0U3HZIntroduction of Radioactive Substance into Joints, Percutaneous Approach
- 3E0U3KZIntroduction of Other Diagnostic Substance into Joints, Percutaneous Approach
- 3E0U3NZIntroduction of Analgesics, Hypnotics, Sedatives into Joints, Percutaneous Approach
- 3E0U3SFIntroduction of Other Gas into Joints, Percutaneous Approach
- 3E0U3TZIntroduction of Destructive Agent into Joints, Percutaneous Approach
- 3E0U4GCIntroduction of Other Therapeutic Substance into Joints, Percutaneous Endoscopic Approach
- 3E0V0GBIntroduction of Recombinant Bone Morphogenetic Protein into Bones, Open Approach
- 3E0V0GCIntroduction of Other Therapeutic Substance into Bones, Open Approach
- 3E0V305Introduction of Other Antineoplastic into Bones, Percutaneous Approach
- 3E0V30MIntroduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach
- 3E0V328Introduction of Oxazolidinones into Bones, Percutaneous Approach
- 3E0V329Introduction of Other Anti-infective into Bones, Percutaneous Approach
- 3E0V33ZIntroduction of Anti-inflammatory into Bones, Percutaneous Approach
- 3E0V36ZIntroduction of Nutritional Substance into Bones, Percutaneous Approach
- 3E0V37ZIntroduction of Electrolytic and Water Balance Substance into Bones, Percutaneous Approach
- 3E0V3BZIntroduction of Anesthetic Agent into Bones, Percutaneous Approach
- 3E0V3GBIntroduction of Recombinant Bone Morphogenetic Protein into Bones, Percutaneous Approach
- 3E0V3GCIntroduction of Other Therapeutic Substance into Bones, Percutaneous Approach
- 3E0V3HZIntroduction of Radioactive Substance into Bones, Percutaneous Approach
- 3E0V3KZIntroduction of Other Diagnostic Substance into Bones, Percutaneous Approach
- 3E0V3NZIntroduction of Analgesics, Hypnotics, Sedatives into Bones, Percutaneous Approach
- 3E0V3TZIntroduction of Destructive Agent into Bones, Percutaneous Approach
- 3E0V4GCIntroduction of Other Therapeutic Substance into Bones, Percutaneous Endoscopic Approach
- 3E0W305Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach
- 3E0W30MIntroduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach
- 3E0W328Introduction of Oxazolidinones into Lymphatics, Percutaneous Approach
- 3E0W329Introduction of Other Anti-infective into Lymphatics, Percutaneous Approach
- 3E0W33ZIntroduction of Anti-inflammatory into Lymphatics, Percutaneous Approach
- 3E0W36ZIntroduction of Nutritional Substance into Lymphatics, Percutaneous Approach
- 3E0W37ZIntroduction of Electrolytic and Water Balance Substance into Lymphatics, Percutaneous Approach
- 3E0W3BZIntroduction of Anesthetic Agent into Lymphatics, Percutaneous Approach
- 3E0W3GCIntroduction of Other Therapeutic Substance into Lymphatics, Percutaneous Approach
- 3E0W3HZIntroduction of Radioactive Substance into Lymphatics, Percutaneous Approach
- 3E0W3KZIntroduction of Other Diagnostic Substance into Lymphatics, Percutaneous Approach
- 3E0W3NZIntroduction of Analgesics, Hypnotics, Sedatives into Lymphatics, Percutaneous Approach
- 3E0W3TZIntroduction of Destructive Agent into Lymphatics, Percutaneous Approach
- 3E0X33ZIntroduction of Anti-inflammatory into Cranial Nerves, Percutaneous Approach
- 3E0X3BZIntroduction of Anesthetic Agent into Cranial Nerves, Percutaneous Approach
- 3E0X3GCIntroduction of Other Therapeutic Substance into Cranial Nerves, Percutaneous Approach
- 3E0X3TZIntroduction of Destructive Agent into Cranial Nerves, Percutaneous Approach
- 3E0Y304Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Percutaneous Approach
- 3E0Y305Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach
- 3E0Y30MIntroduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
- 3E0Y328Introduction of Oxazolidinones into Pericardial Cavity, Percutaneous Approach
- 3E0Y329Introduction of Other Anti-infective into Pericardial Cavity, Percutaneous Approach
- 3E0Y33ZIntroduction of Anti-inflammatory into Pericardial Cavity, Percutaneous Approach
- 3E0Y36ZIntroduction of Nutritional Substance into Pericardial Cavity, Percutaneous Approach
- 3E0Y37ZIntroduction of Electrolytic and Water Balance Substance into Pericardial Cavity, Percutaneous Approach
- 3E0Y3BZIntroduction of Anesthetic Agent into Pericardial Cavity, Percutaneous Approach
- 3E0Y3GCIntroduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Approach
- 3E0Y3HZIntroduction of Radioactive Substance into Pericardial Cavity, Percutaneous Approach
- 3E0Y3KZIntroduction of Other Diagnostic Substance into Pericardial Cavity, Percutaneous Approach
- 3E0Y3NZIntroduction of Analgesics, Hypnotics, Sedatives into Pericardial Cavity, Percutaneous Approach
- 3E0Y3SFIntroduction of Other Gas into Pericardial Cavity, Percutaneous Approach
- 3E0Y3TZIntroduction of Destructive Agent into Pericardial Cavity, Percutaneous Approach
- 3E0Y4GCIntroduction of Other Therapeutic Substance into Pericardial Cavity, Percutaneous Endoscopic Approach
- 3E0Y704Introduction of Liquid Brachytherapy Radioisotope into Pericardial Cavity, Via Natural or Artificial Opening
- 3E0Y705Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening
- 3E0Y70MIntroduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening
- 3E0Y7SFIntroduction of Other Gas into Pericardial Cavity, Via Natural or Artificial Opening